• LAST PRICE
    0.8000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.8000
  • Day Range
    ---
  • 52 Week Range
    Low 0.5103
    High 6.9000
  • Volume
    115
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeCWBR
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCWBR
CohBar Inc
2.3M
-0.2x
---
United StatesQNRX
Quoin Pharmaceuticals Ltd
2.3M
-0.2x
---
United StatesSLRX
Salarius Pharmaceuticals Inc
2.4M
-0.1x
---
United StatesDRMA
Dermata Therapeutics Inc
2.3M
-0.1x
---
United StatesCPMV
Mosaic Immunoengineering Inc
2.3M
-2.2x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
2.4M
-0.1x
---
As of 2024-04-26

Company Information

CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.

Contact Information

Headquarters
1455 Adams Drive, Suite 1308MENLO PARK, CA, United States 94025
Phone
650-446-7888
Fax
302-655-5049

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.3M
Revenue (TTM)
$0.00
Shares Outstanding
2.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.58
EPS
$-4.36
Book Value
$5.27
P/E Ratio
-0.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.